Merck & Co., Inc. (ETR: 6MK)

Market Cap	240.69B
Revenue (ttm)	56.64B
Net Income (ttm)	10.89B
Shares Out	n/a
EPS (ttm)	4.29
PE Ratio	22.10
Forward PE	n/a
Dividend	2.89 (3.01%)
Ex-Dividend Date	Dec 16, 2024

Volume	2,980
Average Volume	897
Open	95.00
Previous Close	96.10
Day's Range	94.80 - 96.00
52-Week Range	89.60 - 125.60
Beta	0.41
RSI	46.78
Earnings Date	Feb 4, 2025

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M−M−R II, Variv...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1891
• Employees: 72,000
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: 6MK

Financial Performance

In 2023, Merck & Co.'s revenue was $60.12 billion, an increase of 1.40% compared to the previous year's $59.28 billion. Earnings were $365.00 million, a decrease of -97.49%.

Financial numbers in USD